Jean M. Franchi
Independent DirectorMs. Jean M. Franchi, CPA is a Director at VectorY. She serves as Chief Financial Officer of Disc Medicine, Inc since February 7, 2024. She served as the Principal Accounting Officer of Replimune Group, Inc. since April 1, 2020. Ms. Franchi had been the Chief Financial Officer at Replimune Group, Inc. since December 12, 2019 until June 2023 and served as its Compliance Officer, Treasurer and Secretary since December 09, 2019. She has been an Independent Director of Biodesix, Inc. since April 2020. She served as Independent Non-Executive Director at Visioneering Technologies, Inc. since December 19, 2017 until December 2022. Ms. Franchi is a highly regarded business leader with experience in building and leading senior corporate and divisional financial teams from the research and development stage through product launch and commercial operations. Her experience spans both the public and private pharmaceutical, biotech and diagnostics sectors. She served as Chief Financial Officer and Treasurer of Merrimack Pharmaceuticals, Inc. since August 12, 2017 until June 28, 2019. Ms. Franchi has been a Director of Virotec International Ltd since December 2017. She has extensive experience in the financial management of biotechnology companies. Ms. Franchi served as the Chief Financial Officer and Treasurer of Dimension Therapeutics, Inc. since August 6, 2015 until July 28, 2017 and served as its Secretary until July 28, 2017. At Dimension Therapeutics, she was responsible for all financial activities and related business strategy, including the company’s initial public offering in 2015. From 1995 to 2011, she mainly filled roles at Genzyme Corporation in financial management (Sold to Sanofi in 2011) such as Senior Vice President of Business Unit Finance and Vice President of Finance and Controller, Product Line and International Group. She served as Senior Vice President of Corporate Finance at Genzyme Corporation. Ms. Franchi managed a team of finance professionals serving Genzyme’s diverse business units as financial Partners to senior management with a focus on both strategic and commercial operations. She served as the Chief Financial Officer of Good Start Genetics, Inc. since February 2012 until July 28, 2015. She served in accounting, finance and sales operations for diagnostic companies’ bioMerieux Vitek and API, a former division of American Home Products. She serves as Member of Supervisory Board at Dynacure SAS. Ms. Franchi is an experienced in finance executive and operational leader with more than three decades of experience in the life sciences industry. She has experience in the biotechnology and life sciences industry where she has held senior financial management roles at both U. S. and international companies. She had been Director of Biophytis SA since June 16, 2017 until July 07, 2021. She serves as Director of Biophytis BSA. She earned her Certified Public Accountant Certificate in Massachusetts. She holds a B.B.A. degree from Hofstra University and successfully completed the Uniform Certified Public Accountant Examination.
Positions
- Company NameBiodesix, Inc.Stock CodeBDSXPositionIndependent DirectorColleagues
- SHScott HuttonPresident, CEO & Director
- JPJohn PatienceIndependent Chairman
- RHRobin Harper CowieCFO, Secretary & Treasurer
- HRHeinrich RoderFounder & CTO
- GAGary Anthony PestanoChief Scientific Officer
- JOJessica OlbrichtVice President of Human Resources
- MWMatthew W. StrobeckIndependent Director
- HMHany MassaranyIndependent Director
- Company NameDisc Medicine, Inc.Stock CodeIRONPositionChief Financial OfficerColleagues
- DWDonald William NicholsonExecutive Chairman
- JDJohn D. QuiselCEO, President & Director
- JMJean M. FranchiChief Financial Officer
- JYJonathan YuChief Opearating Officer
- WJWilliam Jacob SavageChief Medical Officer
- BMBrian MacDonaldFounder & Chair of Scientific Advisory Board
- KJKevin J. BittermanIndependent Director
- WRWilliam R. WhiteIndependent Director
